SIGN-UP NOW! SIGN-UP NOW! Click to become a VoiceAmerica Member for Free!
Voiceamerica radio logo
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

February 02nd 2016:Introduction to XBiotech and their Novel True Human'TM' Approach

This episode introduces XBiotech, developer of True Human(TM) therapeutic antibodies. XBiotech has an exciting pipeline of product candidates in various areas of medicine. The Company recently announced the launch of a research and development program to develop a first-in-class oral monoclonal antibody against Clostridium difficile (C.difficile) infection. The Company will discuss the need for an effective C.difficile therapy, their novel approach to treating the disease as well as efficiency in their manufacturing technology. Join guests: Dr. Michael Stecher, Medical Director, Dr. Sushma Sh

Read more
Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guests

Guest Image

Dr Michael Stecher MD

Dr Michael Stecher is the Medical Director of XBiotech. Dr. Stecher has served as Medical Director since June 2010 and has worked to develop XBiotech's Clinical Program to treat Chronic Inflammatory Disease through targeting the interleukin-1 system, collaborating with key opinion leaders in fields of Endocrinology, Oncology, Cardiovascular medicine, and Dermatology. Dr. Stecher is Board Certified in Family Medicine and a graduate from the University of Kansas School of Medicine.
Read more
Guest Image

Dr Sushma Shivaswamy, PhD

Dr Sushma Shivaswamy, Vice President of Research and Development; Dr. Shivaswamy joined XBiotech in May 2009 as a Senior Research Scientist and quickly advanced to lead the R&D group as Director of Research. Dr. Shivaswamy's academic studies involved elucidating mechanisms for regulation of gene expression. Prior to joining XBiotech, Dr. Shivaswamy was a postdoctoral researcher a the Center for Systems and Synthetic Biology at the University of Texas of Austin. She has a Ph.D. degree in Molecular Biology from the Center of Cellular and Molecular Biology, India.
Read more
Guest Image

Kelly Thornburg

Mr. Thornburg joined XBiotech as Senior Vice President of Operations in June 2015. In this capacity Mr.Thornburg will be responsible for Manufacturing & Quality functions. Prior to joining XBiotech, Mr. Thornburg worked at Amgen, Inc. for sixteen years, most recently serving as the Executive Director Quality Site Head at the Amgen Colorado manufacturing site. He was responsible for all aspects of Quality Operations including QA, QC, Validation, Compliance, and GMP Training. In his tenure at Amgen, Mr. Thornburg supported approval and commercialization of four new protein therapeutic products, provided leadership at both the Colorado and Puerto Rico Operations sites, and worked extensively
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 19/12/2017 10:00 19/12/2017 11:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more This episode introduces XBiotech, developer of True Human(TM) therapeutic antibodies. XBiotech has an exciting pipeline of product candidates in various areas of medicine. The Company recently announced the launch of a research and development program to develop a first-in-class oral monoclonal antibody against Clostridium difficile (C.difficile) infection. The Company will discuss the need for an effective C.difficile therapy, their novel approach to treating the disease as well as efficiency in their manufacturing technology. Join guests: Dr. Michael Stecher, Medical Director, Dr. Sushma Shivaswamy, Vice President of Research and Development, and Kelly Thornburg, Senior Vice President of Operations, as they discuss how XBiotech is pioneering a new era in the discovery and development of targeted antibodies therapeutics. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
GPlus Facebook Twitter Linkedin Social Media
presspass-banner